Connect with us

Cannabis News

World Health Organization Won’t Ease Coca Leaf Ban, Even As Review Found Prohibition Is More Dangerous Than The Plant

Published

on

“It is unacceptable for humanity to demonize a sacred medicinal plant. It was a political decision rather than a scientific one.”

By Mattha Busby, Filter

The The World Health Organization had a historic opportunity to ease the strict global ban on the coca leaf-ban, campaigners said, “racist and colonial” the roots. But the agency has decided not to.

WHO expert review he determined in September how millions of people in the Andes consume the coca leaf daily as part of a long-standing cultural practice without significant negative effects, and conversely that coca control strategies are associated with significant public health harm.

And yet, on December 2nd, the WHO’s Expert Committee on Drug Dependence (ECDD) recommended that the plant be kept in Annex I of the United Nations drug treaties—the most restrictive category of control—because coca leaves can be converted relatively easily into cocaine.

“The simplicity of extracting cocaine from cocaine and its high yield and profitability are well known,” ECDD wrote. “The Commission has also examined evidence of significant increases in the cultivation of cocaine and the production of cocaine-related substances in the context of significant and growing public health concerns about the use of cocaine. In this context, the Commission believes that the reduction or elimination of international controls on the coca leaf may pose a particularly serious risk to public health.”

The commission noted a 34 percent year-on-year increase in cocaine production in 2023, with some countries experiencing historically high levels. But supporters of reform emphasize that coke is not cocaine. They point out that the WHO review supports the plant’s medical potential and the lack of evidence of problematic coca leaf use anywhere in the world — two key criteria a drug must meet to be placed on a less restrictive schedule.

“It is unacceptable for humanity to demonize a sacred medicinal plant”, Jaison Perez Villafaña, guardian of wisdom or mother From the Arhuaco community in Colombia, he said The filter. “It was a political decision rather than a scientific one. Coca leaf (help) is not to blame for the fact that humans with economic interests turned it into cocaine”.

The ECDD said it recognized that “the coca leaf has important cultural and therapeutic value to indigenous peoples and other communities and that there are exceptions to the traditional use of the coca leaf in certain national settings.” A coalition of indigenous coca leaf producers and consumers he wrote The WHO in October asked the UN body to “clearly distinguish” between traditional coca use and cocaine-related issues.

Steve Rolles, senior policy analyst at the Transform Drug Policy Foundation, called the WHO’s suggestion that keeping coca on Schedule 1 would limit cocaine production “ridiculous”, saying the decision exposed the “moral and scientific failure” of drug control worldwide.

“While we might expect them to emerge from political institutions embedded in drug war narratives, there was a sense that the more objective, scientific and nominally independent corners of the UN would maintain a level of pragmatism and principle, even if their recommendations were later rejected by UN political entities.” he wrote It’s LinkedIn.

“The dangers of cocaine powder or smoked crack cocaine, creations of the global North, which is also by far the largest market for both, depend on the traditional use of coca, chewed or in tea, which only occurs in the South,” added Rolles. “It is the global South where the burden of the failed war on cocaine and the criminalization of entire cultures is felt most acutely.”

In 2020, following a WHO recommendation, the United Nations Commission on Narcotic Drugs voted to ease international controls on cannabis, recognizing its medical value after decades of “referral madness”. For reform advocates, the decision represented a slow and delayed shift to evidence-based programming. That is why there was hope that the UN system could also separate the coca leaf — which contains less than 1 percent of the alkaloid cocaine — from the refined powder that feeds global demand.

However, coca will continue to be treated as if it has the same risk profile as cocaine, after a WHO review confirmed that coca chewing has not caused any documented deaths, is not associated with high addiction or “abuse” potential, and has possible therapeutic applications, from anti-inflammatory effects to modest improvements in post-meal glucose.

“The WHO decision is deeply disappointing and disturbing,” Ann Fordham, executive director of the International Council on Drug Policy, said in a press release. “This was no ordinary study, it was a critical test of the UN drug control system. The Commission has demonstrated that it cannot objectively assess the evidence or consider the human rights implications of prohibition. Instead, it has chosen to reinforce the racist and colonial foundations of international drug control. This decision makes it clear that the system is broken and resistant to meaningful reform.”

Experts have long argued that the logic behind the coca ban is selective and ignores existing treaty precedent. Plants such as ephedra used to manufacture methamphetamine, psilocybin-containing mushrooms, and cacti that produce mescaline remain unscheduled at the plant level, although they are used to produce controlled substances.

While open persecution of coca chewers has eased in the Andes, the ban still shapes daily life in parts of the region, from farmers losing crops to stopping aerial fumigation campaigns, eradication forces and communities caught between the networks that dominate the cocaine trade. In a September study, an independent group of experts hired by the WHO said that studies that showed exposure to harmful glyphosate-based pesticides such as Roundup, a probable carcinogen, by aerial spraying of coca crops by authorities “increased the number of abortions and increased the number of medical consultations related to dermatological and respiratory diseases in communities”.

The review added that another study showed that forced coca eradication encouraged coca growers to increase production through the use of toxic agrochemicals “on more or subsequent coca plots, increasing exposure to these chemicals.”

Villafaña and other indigenous leaders have warned that these pressures are cultural violence. Coca is central to Andean communities’ spiritual practice, conflict resolution, work, ceremony, and community health; however, using it outside of the narrow “traditional” exemptions puts people at risk of criminal penalties.

“It would be useful for us as a culture,” said Villafaña, “if the world recognized it as a sacred plant and did not demonize it.” But, he added, the decision would not otherwise affect his community, as its members will continue to chew coca as they have always done.

This the article Originally published by the author the filteran online magazine that deals with drug use, drug policy and human rights from a harm reduction perspective. Keep the filter on Bluesky, X or Facebookand sign up for their newsletter.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

“UK medical cannabis is maturing”

Published

on

By

The UK cannabis market has grown steadily over the past five years, although not always in the way operators had hoped. New brands and imported products have driven much of the expansion, while domestic cultivation has slowed. Alexander Mountain has seen this from the inside long before most people in the industry knew it existed. “I’ve been waiting for this since 2009,” says the founder of growing consultancy Trichome Solutions.

Regulations, compliance, EU-GMP requirements, all of which have made getting a facility off the ground a multi-year exercise. “I’ve worked with organizations and seen firsthand that it takes three, four, even five years to get going,” says Alexander. “It’s a tough market to break into in the UK, which in itself slows down the overall maturation.” The last six months, however, have brought about a change. “There are now clear goals and programs for business. An almost militant approach to protocols. It’s starting to feel like the rest of the EU and Canada.”

© Trichome Solutions

Capitalization and cultivation
Early investment in cannabis in the UK came largely from private capital, and the gap between capitalization and cultivation know-how cost many operators dearly. Consultants were brought in to design and build the facilities, but rarely stayed to operate them. The result was a facility that had to be rebuilt almost as soon as it opened. “A lot of adjustments, changes in workflows, logistical expansion,” says Alexander. “This, of course, requires more capital. This delays profitability and, in some cases, leads to employee burnout.” The model he believes in is the owner-operator structure that has worked in markets such as the US, Canada and Thailand.

In terms of cultivation, genetic selection and post-harvest are where Alexander gives most of his attention. Seasonal changes in the UK favor indoor parameters where possible, although low-light greenhouses have worked for some operators with adequate supplementary lighting. Getting the right genetics for the specific market drives early success and patient retention. Post-harvest, however, he believes the sector is constantly underestimating. “I focus a lot on preserving the plant material and maintaining its chemical profile, particularly cannabinoids, terpenes and volatile sulfur,” he says. “Even simple things, like having enough space to dry properly, seem like common sense. But unless you’ve actually done it, you don’t always realize how important those details are to the quality of the final product.”

UK cannabis demand
Patient demand in the UK has been shaped by the equity market, and licensed operators are working to close this gap. The dynamics here are different from other markets. In Germany and Canada, THC content drives purchasing decisions. In the UK, Alexander is seeing more focus on taste, aromas and the overall experience. “With the amount of choices coming in through imports, people are finding their own strains and becoming more selective,” he says. Closing this gap, in his opinion, involves the farmers as much as the prescribers. “Patient education and support should come from doctors. Producers should teach them about their products. I think growers should invite prescribers more often.”

Over the next three to five years, Alexander expects reliance on imports to ease as domestic supply chains develop and the market stabilizes. He says that there will be operators who come out from the other side, specialized ones. R&D, heritage genetics, premium indoor and post-harvest optimization. “We are now working in the international cannabis industry,” he says. “With comparisons, going on a flight, there is no room for complacency. The operators who find their niche and really excel in it will be the ones who build a strong identity and remain competitive in the cannabis space.”

For more information:
Trichoma solutions
(email protected)
trichomesolutions.com
Linkedin
Instagram

Continue Reading

Cannabis News

DC Mayor Proposes To Let Medical Marijuana And Alcohol Companies Partner On THC Drinks

Published

on

By

The mayor of Washington DC is proposing medical marijuana companies partner with local breweries and distilleries to produce cannabis-infused and non-alcoholic beverages for sale in the nation’s capital.

Under the partnership envisioned by Mayor Muriel Bowser’s (D) Medical Cannabis Beverage Products Amendment Act of 2026, alcohol companies can apply for a medical cannabis production endorsement at a cost of $500 per year to manufacture cannabis beverages, and medical marijuana companies can apply for a $1,000 annual endorsement to import cannabinoids for production.

All beverages would have to be tested by a locally licensed laboratory, and there would be a six percent sales tax on beverages.

“This is an opportunity to support two local industries and keep businesses in DC,” Bowser said in a press release. “We have great local brewers and distillers in our city, we have a strong medical cannabis market, and this is a new opportunity for those two markets to collaborate and create a safe, smoke-free alternative for DC patients”

Breweries and distilleries would not be able to sell cannabis beverages directly to consumers, and the finished products would instead go to medical marijuana manufacturers for testing and distribution.

Sales would be limited to registered medical cannabis patients through dispensaries, and drinks could not be purchased at bars, restaurants, liquor stores and grocery stores.

“It makes sense for the District’s medical cannabis and alcohol manufacturing industries to collaborate to produce medicinal cannabis beverages,” said Fred Moosally, director of the Alcoholic Beverages and Cannabis Administration. he said. “Providing a legal way for our local breweries and distilleries to use their expertise in beverage production is the next step in reaching DC’s medical cannabis market and supporting our local business ecosystem.”

A press release from the mayor’s office said the proposal “works to solve the manufacturing challenges of the medical cannabis industry while providing additional revenue for DC’s local craft beverage producers.”

“Using the existing local bottling infrastructure, DC will expand smokeless therapeutic options for medical cannabis patients, provide additional revenue for the local industry and continue to grow the District’s economy,” he said.

The legislation is now before the District of Columbia Council for consideration.

Although Congress has consistently blocked DC’s legalization of recreational marijuana sales with a pilot approved each year, local officials have worked. expand access through the existing cannabis market for example, allowing residents and even visiting tourists to self-certify without the need for a medical recommendation.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

We’re a small grow, which means we can control things very well

Published

on

By

At 5,000 square feet, Flora Arbor is about as small as a licensed cannabis grower can legally get. That’s not the problem the company is trying to solve. “We’re a very small breed, which means we can control things very well.” he says David Myrowitz, director of cultivation. “It also means that we have to be successful in every round.” Three flower cells, collected in three weeks. There is no such thing as a bad lot to disappear into a larger average. Every shift counts, and the operation is built around that reality.

It starts in the pump room
Reverse osmosis water is fed into holding tanks, nutrients are mixed by an Agrowtek fertigation machine, and the entire system runs from a GCX controller that monitors moisture sensors, dissolved solids, and soil temperature in every room. Canopy sensors feed directly into HVAC, which Flora Arbor runs on Cultiva units. “If you talk to any grower, any grower, they’ll tell you the number one thing for successful growing is having a good HVAC system,” says David. “There is somewhere that we don’t have expenses.”

© Flora Arbor

Genetics and cells
Mother plants are removed every three to six months, so cuttings are always taken from young stock. The clones move from the humidity domes to a humidity-controlled room, then to the vegetables, where a crop-correction protocol runs several irrigation streams per day to encourage growth. Moisture sensors in the grow bags track each drying cycle, and daily watering patterns are revised based on the goals of the grow system.

The flower rooms have a double-level system, with taller plants at the bottom, shorter ones at the top, grouped to keep microclimates outside and an even distribution of light. The second mesh is lowered as the plants develop to give each bud site its own square and keep airflow moving through the canopy.

In a recent route, rooms from different phases of the cycle were working at the same time. Hawaiian Rain has been crossed with permanent marker, disk chips, cereal milk. David pointed to the development of crystals in the Hawaiian Rain cross, the citrus resin charge of Disco Fries, the height management challenge of pushing a cultivar as high as possible without burning them in the lights. “We try to have a nice spread of genetics, a nice representative of each flavor profile and effect, to make sure everyone can get something they like,” he says.

Crossing the finish line
Post-harvest is managed at home, by hand. The product is sorted on the cutting table A-Bd, B-Bud and cutting table, strictly separated, the grade on the label means something. The tiered structure also serves a second purpose. “We think it’s really important to make sure quality flowers are available to people of all means, not just people who can afford the premium,” says David. The three-week harvest cycle is Flora Arbor’s main argument for the consumer. Small batches, constant rotation, nothing stored.

“Every time you get a bag, it’s going to be fresh, freshly picked grass,” says David. “It’s not something that’s been sitting in some MSO’s vault for six months because they’ve collected 2,000 pounds and can’t sell it.” The bet is that in a market where no one has solved the consistency complaint, being small enough to catch all the cattle is more valuable than the economies of scale you allow to get there.

For more information:
Flora Arbor
1300 Abbott Dr, Elgin, IL 60123
847-504-8450
(email protected)
floraarbor.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media